what is a normal factor viii level?

Answer 1

We don't normally measure Factor VIII levels. Usually we test the intrinsic clotting pathway by measureing APTT - Activated Partial Thromboplastin Time.

Where I've looked it seems that they express Factor VIII levels as a %age of normal. Barely noticeable Hemophilia at 10-30%, mild at 5-10% of normal levels, and severe at <=1% of normal Factor VIII levels.

It is possible to measure them, but it is costly and usually only in the realm of the Hematologist specialists.

Answer 2

Hemophilia A is the most common type of hemophilia. It is also known as factor VIII deficiency or classic hemophilia. It is largely an inherited disorder in which one of the proteins needed to form blood clots is missing or reduced. In about 30% of cases, there is no family history of the disorder and the condition is the result of a spontaneous gene mutation.

Answer 3

Dosage and Administration: IV administration only. The maximum rate of administration is product dependent. See package insert for administration and laboratory monitoring details.

Hemophilia A:
The circulating half-life of factor VIII is 10-12 hours, but in the first 36-48 hours post-op or post-life-threatening trauma, the rate of factor consumption is relatively high. In such cases an every 8-hr schedule should be maintained.

Dosage is based on the desired factor VIII:C increase (%): A 100% AHF level is 1 international unit (IU) of Factor VIII:C per ml of plasma (1.0 IU/ml). Most bleeding is successfully treated if levels are >30% of normal. In life-threatening or surgical situations, initiate therapy to achieve 100% level and adjust so that the expected level 8 hours after infusion does not fall below 50% during the treatment schedule.

One can assume that 1 IU of Factor VIII/kg body weight will increase the patient’s level by 2% (0.02 IU/ml). Therefore, if the patient’s level is 1% or less (0.01 IU/ml), which is true in severe hemophilia, a dose of 40 IU/kg body weight will raise the level to 80%, in the absence of any inhibitors.

Dosage and desired level of AHF vary depending upon the nature of the bleeding (hemarthrosis, intramuscular, neurological, surgical, etc) and hematologic or transfusion medicine consultation is strongly recommended.

Initiate therapy when the following criteria are met: Patient has diagnosis of hemophilia A and has bleeding or physical trauma or surgery is anticipated. A hemophilia patient can tell when he is bleeding; do NOT do joint aspirations or other invasive diagnostic procedures to decide on therapy. Treat until bleeding stops and/or cause has been ameliorated, usually 1- 2 days following a joint hemorrhage, 7 to 10 days after soft tissue trauma or surgery.

von Willebrand Disease:
Humate-P is labeled with both factor VIII:C and von Willebrand factor/Ristocetin cofactor activity (vWF:RCof) levels. In von Willebrand disease, expected levels of recovery are 1.5 IU/dL rise per IU/kg vWF:RC of administered. 40-80 IU vWF:RCof per kg body weight given every 8-12 hours would be expected to lead to 100% replacement of circulating levels of von Willebrand factor. See package insert for detailed dosing information.

Contraindications:Hypersensitivity to mouse (Monoclate-P, Monarc-M, Hemofil M) or hamster (Helixate FS, Kogenate FS, Recombinate) protein.

Humate-P may contain trace amounts of Anti A and Anti B isoagglutinins with a consequent small risk of a positive DAT or hemolysis after infusion.

Patients with hemophilia A and factor inhibitors should not receive additional AHF and require highly specialized treatment. See other sections of these Guidelines (FEIBA, NovoSeven, Porcine AHF) for details. Treatment of acquired circulating anticoagulants in hemophilia patients, or appearing spontaneously in patients with Waldenstrom’s, lymphoma or immunologic disease, is complex and should not be undertaken without specific consultation.

Alternative Therapy: None.

Answer 4

sorry, i dont understand your question "viii" ?